XOMA Announces Retirement of Fred Kurland and Appointment of Thomas Burns as Chief Financial Officer
March 03 2015 - 7:00AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, today announced Thomas
Burns, Vice President, Finance, will succeed Fred Kurland as Chief
Financial Officer when Mr. Kurland retires from his role as Vice
President, Finance, Chief Financial Officer and Secretary effective
April 3, 2015. Mr. Burns will report directly to John Varian, Chief
Executive Officer.
"I have enjoyed every moment of my time at XOMA. The team has
made significant progress in the past three years, and the
management team today is very strong. I have every confidence the
Company will achieve its goal of becoming a commercial organization
marketing its products to specialist prescribers in the United
States," commented Mr. Kurland. "I am looking forward to spending
time with my family, particularly my grandchildren."
"Fred has been an integral part of the team that has established
XOMA as a leader in the discovery and development of therapeutic
antibodies. He has ensured we have the capital we need to advance
gevokizumab towards XOMA's first Biologics Licensing Application
and expand our clinical development pipeline," stated Mr. Varian.
"Tom has been with XOMA for 8 years, and he has grown significantly
under Fred's mentorship. This promotion is well deserved, as Tom
has shown he has all of the necessary skills to be a very
successful CFO."
"I joined XOMA and the biotechnology industry from the high-tech
industry as we have the opportunity to have a significant impact on
patients' lives. We have an exciting year ahead of us at XOMA, and
I am looking forward to developing and implementing the financial
strategies that will be required to see the Company transform into
a commercial organization," Mr. Burns remarked.
Mr. Burns joined the XOMA finance team in 2006 and has been an
essential member in the Company's financing and financial reporting
activities. Prior to XOMA, he held multiple senior financial
management positions at high-tech companies including Mattson
Technology, IntruVert Networks (acquired by McAfee), Niku
Corporation (acquired by Computer Associates) and Conner
Technology. Mr. Burns received his Bachelor's degree from Santa
Clara University and his Masters of Business Administration from
Golden Gate University.
About XOMA Corporation
XOMA's innovative product candidates are the result of the
Company's expertise in developing ground-breaking monoclonal
antibodies, including allosteric modulating antibodies, which has
created opportunities to develop new classes of therapeutic
antibodies with the potential to treat a wide range of human
diseases. XOMA is developing its lead product gevokizumab (IL-1
beta modulating antibody) with SERVIER through a global Phase 3
program for Behçet's disease uveitis and non-infectious uveitis and
a Phase 3 program in pyoderma gangrenosum, as well as ongoing
proof-of-concept studies in other IL-1-mediated diseases. XOMA's
scientific research has also produced the XMet program, which
consists of three classes of Selective Insulin Receptor Modulators
(SIRMs) antibodies, including XOMA 358, the lead product candidate
in the XMetD program, that are being investigated for the treatment
of abnormal metabolic states. XOMA's extensive antibody expertise
includes antibody discovery, optimization, cell line and process
development.
More detailed information can be found at www.xoma.com.
Forward-Looking Statements
Certain statements contained in this press release including,
but not limited to, statements related to anticipated timing of
initiation and completion of clinical trials, Proof-of-Concept
trials, anticipated size of clinical trials, regulatory approval of
unapproved product candidates, sufficiency of our cash resources
and anticipated levels of cash utilization, or statements that
otherwise relate to future periods are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
statements are based on assumptions that may not prove accurate,
and actual results could differ materially from those anticipated
due to certain risks inherent in the biotechnology industry and for
companies engaged in the development of new products in a regulated
market. Potential risks to XOMA meeting these expectations are
described in more detail in XOMA's most recent filing on Form 10-K
and in other SEC filings. Consider such risks carefully when
considering XOMA's prospects. Any forward-looking statement in this
press release represents XOMA's views only as of the date of this
press release and should not be relied upon as representing its
views as of any subsequent date. XOMA disclaims any obligation to
update any forward-looking statement, except as required by
applicable law.
CONTACT: XOMA Corporation
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024